US-based SomaLogic has entered a partnership with Children’s Hospital Colorado for the development of diagnostic tests for childhood diseases.
Both parties will work together to discover protein biomarkers to develop laboratory tests to improve the diagnosis and management of childhood diseases.
The development work will be carried out using SomaLogic’s proteomics SOMAscan assay, which is capable of measuring more than thousand proteins in a small amount of blood or other biological samples.
Robin Deterding will lead the research team. He is serving as director of the Breathing Institute at Children’s Colorado, professor of Pulmonary Medicine in the Department of Pediatrics at the University of Colorado School of Medicine, and chair of the North American Children’s Interstitial and Diffuse Lung Disease Research Network (CHILDRN).
Dr Deterding said: "We have a unique ‘game-changing’ opportunity to rapidly discover and apply blood-based protein biomarkers for the early diagnosis of rare and common paediatric lung diseases, but also for the diagnosis, prognosis and monitoring of many other childhood diseases."
As part of the deal, researchers from both the organisations will work together to analyse the proteins from blood samples obtained from children suffering from disease.
After analysing, those proteins or biomarkers, whose change in concentration is correlated with disease will be selected to serve as a basis for developing in-house diagnostic tests for future clinical use.
SomaLogic chief executive officer Byron Hewett said: "This collaboration with Children’s Hospital and CU School of Medicine faculty is the ideal model for how we would like to see our technology used by academic research centres to make a difference in the lives of patients.
"Their clinical insight and expertise matched to our proteomics expertise should lead to both a deeper understanding of the biology of these devastating diseases, and to new ways to manage them more precisely and effectively."
Image: Children’s Colorado breathing institute director Robin Deterding will lead the research team. Photo: courtesy of Business Wire.